LOS ANGELES, CA--(Marketwire -12/13/11)- NovaBay Pharmaceuticals, Inc. (AMEX: NBY - News) is developing a new class of broad-spectrum antimicrobial for chronic wounds called NeutroPhase® and in an exclusive Expert Briefing report, the founder and Chairman of NovaBay Pharmaceuticals, Ron Najafi, PhD shares insight and briefs biotech investors about the dangers of Chronic non-healing wounds, such as venous stasis ulcers, diabetic ulcers, and pressure ulcers. These wounds are serious unmet medical needs that effect a patient's morbidity and mortality.
NovaBay is a clinical-stage biotechnology company located in Emeryville, CA and is also developing a first-in-class, anti-infective Aganocide® compound (NVC-422) for the local non-systemic treatment and prevention of antibiotic-resistant infections.
The firm's NeutroPhase® has recently garnered much attention within the wound care research community due to a series of studies indicating that it is a safe, effective, broad-spectrum antimicrobial agent against: Gram-positive bacteria including MRSA, VRE, and Bacillus anthraxis, Gram-negative bacteria; yeast; fungi; and Acanthamoeba. NovaBay has conducted several GLP studies indicating broad safety profile of NeutroPhase®.
To read this exclusive Expert Briefing and for more breaking news and analysis of Healthcare sector investing and trading, visit BioMedReports.Com:
Investors interested in make more profitable trades can access BioMedReports' new Complete Database of Clinical Trials and Upcoming FDA and World-Wide Regulatory Decisions at:
News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports.
BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com.